Chris Cooley
Stock Analyst at Stephens & Co.
(3.09)
# 1,137
Out of 5,180 analysts
55
Total ratings
71.05%
Success rate
44.18%
Average return
Main Sectors:
Stocks Rated by Chris Cooley
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| VCEL Vericel | Maintains: Overweight | $39 → $42 | $30.55 | +37.48% | 2 | May 11, 2023 | |
| ALGN Align Technology | Maintains: Overweight | $500 → $375 | $166.26 | +125.55% | 7 | Jul 28, 2022 | |
| COO The Cooper Companies | Maintains: Overweight | $125 → $115 | $69.31 | +65.92% | 9 | Jun 3, 2022 | |
| ALC Alcon | Upgrades: Overweight | $86 → $92 | $73.67 | +24.88% | 4 | May 12, 2022 | |
| PLSE Pulse Biosciences | Maintains: Overweight | $14 → $12 | $19.63 | -38.87% | 2 | Apr 1, 2022 | |
| ANIK Anika Therapeutics | Downgrades: Equal-Weight | n/a | $14.13 | - | 2 | Mar 9, 2022 | |
| ESTA Establishment Labs Holdings | Maintains: Overweight | $88 → $90 | $54.69 | +64.56% | 3 | Nov 10, 2021 | |
| STE STERIS | Maintains: Overweight | $255 → $270 | $219.38 | +23.07% | 5 | Nov 4, 2021 | |
| GKOS Glaukos | Upgrades: Overweight | $60 → $68 | $105.01 | -35.24% | 5 | Nov 3, 2021 | |
| AVNS Avanos Medical | Downgrades: Equal-Weight | $60 → $45 | $13.73 | +227.75% | 2 | Aug 4, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $425 → $275 | $114.93 | +139.28% | 5 | Mar 23, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $56 → $37 | $18.34 | +101.74% | 2 | Mar 23, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $75 → $60 | $61.90 | -3.07% | 3 | Mar 23, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $48 → $35 | $62.93 | -44.38% | 2 | Mar 23, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $60 → $81 | $208.01 | -61.06% | 2 | Feb 22, 2018 |
Vericel
May 11, 2023
Maintains: Overweight
Price Target: $39 → $42
Current: $30.55
Upside: +37.48%
Align Technology
Jul 28, 2022
Maintains: Overweight
Price Target: $500 → $375
Current: $166.26
Upside: +125.55%
The Cooper Companies
Jun 3, 2022
Maintains: Overweight
Price Target: $125 → $115
Current: $69.31
Upside: +65.92%
Alcon
May 12, 2022
Upgrades: Overweight
Price Target: $86 → $92
Current: $73.67
Upside: +24.88%
Pulse Biosciences
Apr 1, 2022
Maintains: Overweight
Price Target: $14 → $12
Current: $19.63
Upside: -38.87%
Anika Therapeutics
Mar 9, 2022
Downgrades: Equal-Weight
Price Target: n/a
Current: $14.13
Upside: -
Establishment Labs Holdings
Nov 10, 2021
Maintains: Overweight
Price Target: $88 → $90
Current: $54.69
Upside: +64.56%
STERIS
Nov 4, 2021
Maintains: Overweight
Price Target: $255 → $270
Current: $219.38
Upside: +23.07%
Glaukos
Nov 3, 2021
Upgrades: Overweight
Price Target: $60 → $68
Current: $105.01
Upside: -35.24%
Avanos Medical
Aug 4, 2021
Downgrades: Equal-Weight
Price Target: $60 → $45
Current: $13.73
Upside: +227.75%
Mar 23, 2020
Maintains: Overweight
Price Target: $425 → $275
Current: $114.93
Upside: +139.28%
Mar 23, 2020
Maintains: Overweight
Price Target: $56 → $37
Current: $18.34
Upside: +101.74%
Mar 23, 2020
Maintains: Overweight
Price Target: $75 → $60
Current: $61.90
Upside: -3.07%
Mar 23, 2020
Maintains: Overweight
Price Target: $48 → $35
Current: $62.93
Upside: -44.38%
Feb 22, 2018
Maintains: Equal-Weight
Price Target: $60 → $81
Current: $208.01
Upside: -61.06%